|
Variables | % |
|
Race | |
White | 49.9% |
African american | 24.8% |
Hispanic & other | 25.4% |
Gender | |
Male | 46.7% |
Female | 53.3% |
Age (years) | |
65 | 60.0% |
≥65 | 40.0% |
Poverty/income ratio | |
1 | 36.3% |
≥1 | 63.7% |
Smoking status | |
Never smoked | 45.4% |
Ever-smoker (currently nonsmoker) | 31.4% |
Current-smoker | 23.1% |
History of CVD (stroke, MI & congestive heart failure) | |
No | 86.9% |
Yes | 13.1% |
Hypertriglyceridemia | |
150 mg/dL | 59.3% |
≥150 mg/dL | 40.7% |
Decreased HDL cholesterol (men ≤ 40 mg/dL/women ≤ 50 mg/dL) | |
No | 62.0% |
Yes | 38.0% |
Blood pressure (≥130/85 mmHg) | |
110 mmHg systolic & 85 mmHg diastolic | 36.8% |
130 mmHg systolic or 85 mmHg diastolic | 63.2% |
Diabetes (FBS, medications for DM & physician diagnosis) | |
110 mg/dL | 74.9% |
110 | 25.1% |
Central obesity (waist circumference: men ≥ 40 inches/women ≥ 35 inches) | |
No | 49.9% |
Yes | 50.4% |
Proinflammatory state (CRP ≥ 3 mg/dL) | |
No | 73.0% |
Yes | 27.0% |
Prothrombotic state (fibrinogen ≥ 350 mg/dL ) | |
No | 71.7% |
Yes | 28.3% |
Metabolic syndrome (meet at criteria for 3 or ATP III criteria) | |
No | 77.9% |
Yes | 22.1% |
Renal dysfunction (eGFR in mL/min/1.73 m and proteinuria) | |
0–59 | 9.5% |
60–89 or eGFR ≥90 with proteinuria | 43.9% |
≥90 with no proteinuria | 46.6% |
Renal dysfunction & metabolic syndrome | |
No metabolic syndrome and no renal dysfunction | 31.9% |
No metabolic syndrome and early renal dysfunction | 24.4% |
No metabolic syndrome and late renal dysfunction | 3.6% |
Metabolic syndrome and no renal dysfunction | 14.7% |
Metabolic syndrome and early renal dysfunction | 19.4% |
Metabolic syndrome and late renal dysfunction | 6.0% |
CVD specific mortality | |
No | 88.2% |
Yes | 11.8% |
Interview/exam to mortality follow-up period in months (mean ± std) | 96.5 [±33.0] |
|